摘要
目的了解新型冠状病毒肺炎(COVID-19)患者体内新型冠状病毒(SARS-CoV-2)特异性抗体—免疫球蛋白(Ig)M、IgG和IgA的应答规律。方法使用酶联免疫吸附试验检测SARS-CoV-2特异性IgM和IgG抗体,使用磁微粒化学发光法检测SARS-CoV-2特异性IgA抗体。结果COVID-19患者血浆中SARS-CoV-2特异性IgM、IgG抗体水平(中位数)在发病后第4周达到峰值,IgA抗体一直处于较低水平。重型患者IgM和IgG抗体水平达到峰值的时间与非重型患者一致,抗体峰值水平高于非重型患者(OD 450中位数:IgM:2.837 vs.1.133,P=0.005;IgG:3.777vs.3.376,P=0.031),发病5周后的抗体水平高于非重型患者(OD 450中位数:IgM:1.454 vs.0.263,P=0.021;IgG:3.136 vs.2.552,P=0.027)。重型患者IgA抗体水平达到峰值的时间晚于非重型患者(第5周vs.第3周),发病第4周和第5周的抗体水平均高于非重型患者(S/CO中位数:第4周:9.654 vs.2.546,P=0.035;第5周:20.580 vs.2.861,P=0.046)。结论SARS-CoV-2感染可引起机体广泛的免疫应答,血清抗体检测在辅助诊断中可发挥重要作用。重型患者产生的抗体应答有一定延迟,但抗体水平高于非重型患者。
Objective To understand the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)specific IgM,IgG and IgA responses in corona virus disease 2019(COVID-19)patients.Method The SARS-CoV-2-specific IgM and IgG levels were determined by the enzyme-linked immunosorbent assay while IgA levels were detected by the chemiluminescence immune detection systems.Results The median antibody levels of IgM and IgG to SARS-CoV-2 in COVID-19 patients’plasma peaked at 4 th week after symptoms onset,while the IgA level maintained a low level.The median antibody levels of IgM and IgG in severe and non-severe patients peaked at 5 th and 4 th week after symptoms onset,respectively.The peak antibody levels were higher in severe patients than those in non-severe patients(median OD 450 value of IgM:2.837 vs.1.133,P=0.005;median OD 450 value of IgG:3.777 vs.3.376,P=0.031).The severe patients exhibited higher IgM and IgG levels than those in non-severe patients after 5 th week(median OD 450 value of IgM:1.454 vs.0.263,P=0.021;median OD 450 value of IgG:3.136 vs.2.552,P=0.027).The severe patients exhibited a delayed time for the peak IgA levels than that in non-severe patients(5 th week vs.3 th week).The IgA levels in 4 th and 5 th week were higher in severe patients than those in non-severe patients(median S/CO value in 4 th week:9.654 vs.2.546,P=0.035;median S/CO value in 5 th week:20.580 vs.2.861,P=0.046).Conclusions The antibody responses to SARS-CoV-2 were widely induced in COVID-19 patients,thus antibody testing might play a vital role in the diagnosis of COVID-19 as a complementary approach to viral nucleic acid assays.Delayed,but stronger,antibody responses were observed in severe patients.
作者
孙颖
黄亚兰
张晓敏
孟君
熊玲红
彭博
房师松
张仁利
SUN Ying;HUANG Ya-lan;ZHANG Xiao-min;MENG Jun;XIONG Ling-hong;PENG Bo;FANG Shi-song;ZHANG Ren-li(Institute of Pathogen Biology,Shenzhen Center for Disease Control and Prevention,Shenzhen,Guangdong 518055,China)
出处
《热带医学杂志》
CAS
2021年第9期1209-1213,共5页
Journal of Tropical Medicine
基金
国家自然科学基金(21705111,81601386)
深圳市科技创新委员会重点项目(JSGG20200207161926465,JSGG20191129144225464)。
关键词
新型冠状病毒
抗体应答
临床分型
SARS-CoV-2
Antibody response
Clinical classifications
